TY - JOUR
T1 - Endothelial activation and fibrotic changes are impeded by laminar flow-induced CHK1-SENP2 activity through mechanisms distinct from endothelial-to-mesenchymal cell transition
AU - Nguyen, Minh T.H.
AU - Imanishi, Masaki
AU - Li, Shengyu
AU - Chau, Khanh
AU - Banerjee, Priyanka
AU - Velatooru, Loka reddy
AU - Ko, Kyung Ae
AU - Samanthapudi, Venkata S.K.
AU - Gi, Young J.
AU - Lee, Ling Ling
AU - Abe, Rei J.
AU - McBeath, Elena
AU - Deswal, Anita
AU - Lin, Steven H.
AU - Palaskas, Nicolas L.
AU - Dantzer, Robert
AU - Fujiwara, Keigi
AU - Borchardt, Mae K.
AU - Turcios, Estefani Berrios
AU - Olmsted-Davis, Elizabeth A.
AU - Kotla, Sivareddy
AU - Cooke, John P.
AU - Wang, Guangyu
AU - Abe, Jun Ichi
AU - Le, Nhat Tu
N1 - Funding Information:
This study received partial funding from the National Institutes of Health (NIH) to JA, N-TL, and JC (HL149303 and HL163857), JA (AI156921), JC (HL148338 and HL157790), and N-TL (HL-134740, HL157790). Acknowledgment
Publisher Copyright:
2023 Nguyen, Imanishi, Li, Chau, Banerjee, Velatooru, Ko, Samanthapudi, Lee, Abe, McBeath, Deswal, Lin, Palaskas, Dantzer, Fujiwara, Borchrdt, Turcios, Olmsted-Davis, Kotla, Cooke, Wang, Abe and Le.
PY - 2023
Y1 - 2023
N2 - Background: The deSUMOylase sentrin-specific isopeptidase 2 (SENP2) plays a crucial role in atheroprotection. However, the phosphorylation of SENP2 at T368 under disturbed flow (D-flow) conditions hinders its nuclear function and promotes endothelial cell (EC) activation. SUMOylation has been implicated in D-flow-induced endothelial-to-mesenchymal transition (endoMT), but the precise role of SENP2 in counteracting this process remains unclear. Method: We developed a phospho-specific SENP2 S344 antibody and generated knock-in (KI) mice with a phospho-site mutation of SENP2 S344A using CRISPR/Cas9 technology. We then investigated the effects of SENP2 S344 phosphorylation under two distinct flow patterns and during hypercholesteremia (HC)-mediated EC activation. Result: Our findings demonstrate that laminar flow (L-flow) induces phosphorylation of SENP2 at S344 through the activation of checkpoint kinase 1 (CHK1), leading to the inhibition of ERK5 and p53 SUMOylation and subsequent suppression of EC activation. We observed a significant increase in lipid-laden lesions in both the aortic arch (under D-flow) and descending aorta (under L-flow) of female hypercholesterolemic SENP2 S344A KI mice. In male hypercholesterolemic SENP2 S344A KI mice, larger lipid-laden lesions were only observed in the aortic arch area, suggesting a weaker HC-mediated atherogenesis in male mice compared to females. Ionizing radiation (IR) reduced CHK1 expression and SENP2 S344 phosphorylation, attenuating the pro-atherosclerotic effects observed in female SENP2 S344A KI mice after bone marrow transplantation (BMT), particularly in L-flow areas. The phospho-site mutation SENP2 S344A upregulates processes associated with EC activation, including inflammation, migration, and proliferation. Additionally, fibrotic changes and up-regulated expression of EC marker genes were observed. Apoptosis was augmented in ECs derived from the lungs of SENP2 S344A KI mice, primarily through the inhibition of ERK5-mediated expression of DNA damage-induced apoptosis suppressor (DDIAS). Summary: In this study, we have revealed a novel mechanism underlying the suppressive effects of L-flow on EC inflammation, migration, proliferation, apoptosis, and fibrotic changes through promoting CHK1-induced SENP2 S344 phosphorylation. The phospho-site mutation SENP2 S344A responds to L-flow through a distinct mechanism, which involves the upregulation of both mesenchymal and EC marker genes.
AB - Background: The deSUMOylase sentrin-specific isopeptidase 2 (SENP2) plays a crucial role in atheroprotection. However, the phosphorylation of SENP2 at T368 under disturbed flow (D-flow) conditions hinders its nuclear function and promotes endothelial cell (EC) activation. SUMOylation has been implicated in D-flow-induced endothelial-to-mesenchymal transition (endoMT), but the precise role of SENP2 in counteracting this process remains unclear. Method: We developed a phospho-specific SENP2 S344 antibody and generated knock-in (KI) mice with a phospho-site mutation of SENP2 S344A using CRISPR/Cas9 technology. We then investigated the effects of SENP2 S344 phosphorylation under two distinct flow patterns and during hypercholesteremia (HC)-mediated EC activation. Result: Our findings demonstrate that laminar flow (L-flow) induces phosphorylation of SENP2 at S344 through the activation of checkpoint kinase 1 (CHK1), leading to the inhibition of ERK5 and p53 SUMOylation and subsequent suppression of EC activation. We observed a significant increase in lipid-laden lesions in both the aortic arch (under D-flow) and descending aorta (under L-flow) of female hypercholesterolemic SENP2 S344A KI mice. In male hypercholesterolemic SENP2 S344A KI mice, larger lipid-laden lesions were only observed in the aortic arch area, suggesting a weaker HC-mediated atherogenesis in male mice compared to females. Ionizing radiation (IR) reduced CHK1 expression and SENP2 S344 phosphorylation, attenuating the pro-atherosclerotic effects observed in female SENP2 S344A KI mice after bone marrow transplantation (BMT), particularly in L-flow areas. The phospho-site mutation SENP2 S344A upregulates processes associated with EC activation, including inflammation, migration, and proliferation. Additionally, fibrotic changes and up-regulated expression of EC marker genes were observed. Apoptosis was augmented in ECs derived from the lungs of SENP2 S344A KI mice, primarily through the inhibition of ERK5-mediated expression of DNA damage-induced apoptosis suppressor (DDIAS). Summary: In this study, we have revealed a novel mechanism underlying the suppressive effects of L-flow on EC inflammation, migration, proliferation, apoptosis, and fibrotic changes through promoting CHK1-induced SENP2 S344 phosphorylation. The phospho-site mutation SENP2 S344A responds to L-flow through a distinct mechanism, which involves the upregulation of both mesenchymal and EC marker genes.
KW - atherosclerosis
KW - CHK1
KW - endothelial activation
KW - fibrotic changes
KW - laminar flow
KW - SENP2
KW - SUMOylation
UR - http://www.scopus.com/inward/record.url?scp=85170686465&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85170686465&partnerID=8YFLogxK
U2 - 10.3389/fcvm.2023.1187490
DO - 10.3389/fcvm.2023.1187490
M3 - Article
C2 - 37711550
AN - SCOPUS:85170686465
SN - 2297-055X
VL - 10
SP - 1187490
JO - Frontiers in Cardiovascular Medicine
JF - Frontiers in Cardiovascular Medicine
M1 - 1187490
ER -